Table 6 Incremental cost-effectiveness calculations for the sensitivity analyses with the dominance report: “No strategies were clearly dominated by any other”
Strategy | Cost (€) | Incremental cost (€) | Effectiveness (QALY) | Incremental effectiveness (QALY) | Cost-efectiveness (€/QALY) | Incremental cost-effectiveness (€/QALY) |
|---|---|---|---|---|---|---|
Alternative 7 | ||||||
EVLT | 2676.89 | 0.113 | 23626.54 | |||
HL/S | 5756.33 | 3079.45 | 0.119 | 0.006 | 48291.39 | 521940.11 |
Alternative 8 | ||||||
EVLT | 2676.89 | 0.360 | 7435.79 | |||
HL/S | 5756.33 | 3079.45 | 0.367 | 0.007 | 15663.49 | 410592.89 |
Alternative 10 | ||||||
HL/S | 924.67 | 0.161 | 5761.163 | |||
EVLT | 1363.55 | 438.89 | 0.171 | 0.010 | 7978.66 | 42200.64 |
Alternative 11 | ||||||
HL/S | 924.67 | 0.328 | 2819.97 | |||
EVLT | 1363.55 | 438.89 | 0.351 | 0.023 | 3884.77 | 18999.42 |
Alternative 12 | ||||||
HL/S | 3028.17 | 0.161 | 18867.08 | |||
EVLT | 3332.13 | 303.97 | 0.171 | 0.010 | 19497.56 | 29227.56 |
Alternative 14 | ||||||
HL/S | 3028.17 | 0.355 | 8530.05 | |||
EVLT | 3332.13 | 303.97 | 0.380 | 0.025 | 8768.77 | 12158.67 |
Alternative 23 | ||||||
HL/S | 924.67 | −0.007 | −127540.23 | |||
EVLT | 1363.55 | 438.89 | −0.003 | 0.004 | −419554.87 | 109721.67 |
Alternative 25 | ||||||
HL/S | 4971.33 | −0.007 | −685701.15 | |||
EVLT | 7030.22 | 2058.89 | −0.003 | 0.004 | −2163144.62 | 514721.67 |